Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASSI: Self-Administered Icatibant for HAE
NCT00997204Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2009
- Primary completion
- Jun 2011
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label trial of icatibant in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoint: Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks at 7 days. Started Sep 2009; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00997204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00997204.